Navigation Links
Oclaro(TM) Hits Milestone With Clarity(TM) Fluorescence Filters
Date:6/16/2009

SAN JOSE, Calif., June 17 /PRNewswire-FirstCall/ -- Oclaro, Inc. (Nasdaq: OCLR) has announced the shipment of its 200,000th Fluorescence Filter for biomedical and analytical instrumentation markets. Oclaro filters are used by leading companies in a wide range of biomedical and analytical applications, including clinical diagnostics, drug discovery, gene quantification, blood analysis, and disease detection. The latest offerings from the Oclaro filter portfolio are on display at LASER World of Photonics 2009 in Munich.

Oclaro Clarity(TM) Filters utilise proprietary AED (Advanced Energetic Deposition) coating technology to produce high performance band pass filters, dichroic mirrors, and laser beam combiners. The AED technology facilitates an environmentally stable hard coating that offers superb resistance, high transmission, and high out-of-band blocking. The state of the art Oclaro automated production facilities enable repeatability and high yield at large volumes, ensuring cost effective manufacturing and value for our customers.

"Oclaro Fluorescence Filters are based on proven telecom technology boasting zero failures in over 65 billion recorded hours of operation," said Yves LeMaitre, EVP and General Manager of the Oclaro Advanced Photonic Solutions (APS) division. "We have been manufacturing Clarity Fluorescence Filters for the biomedical market for over five years and have the expertise to deliver quality, innovative products to this demanding and dynamic market."

The APS division leverages the Oclaro telecom expertise and channels it into biomedical and industrial applications. The Clarity fluorescence filter is a prime example of bringing the best of telecom technology manufacturing into biomedical applications, which represents a strategic focus for the APS division of Oclaro.

The portfolio of Clarity Filters will be on shown at the Oclaro booth (#C1.341) during Laser 2009. For more information, contact min.chen@oclaro.com.

Oclaro was formerly Bookham, Inc. prior to its merger with Avanex Corporation last April. The company also recently announced entering into a definitive agreement with Newport Corporation which, if the transaction closes, will, among other things, provide Oclaro with a portion of the Newport Spectra Physics high power laser diode business, and provide Newport with the existing New Focus business. Oclaro will continue to leverage its cutting edge, high reliability laser diode manufacturing facilities to service industrial, defense and medical markets with high power lasers, VCSELs and Thin Film Filters.

Notes to editors

  1. On April 27, 2009, Bookham, Inc. & Avanex, Corp. merged to create Oclaro, Inc.
  2. LASER World of Photonics will take place 15-18 June 2009 at the New Munich Trade Fair Center
  3. Oclaro will be exhibiting at the LASER World of Photonics exhibition at booth #C1.341
  4. To arrange an interview with representatives of Oclaro before or during the show, please contact Howard Jones on howard@rooftop-pr.com or +44 (0)7500 849 738

About Oclaro

Oclaro, with headquarters in San Jose, California, is a tier 1 provider of high performance optical components, modules and subsystems to the telecommunications market, and is one of the largest providers to metro and long haul network applications. Oclaro, the result of the combination of Bookham, Inc. and Avanex Corporation, leverages proprietary core technologies and vertically integrated product development to provide its broad customer base with cost-effective and innovative optical solutions. The company's Advanced Photonics Division is chartered with driving Oclaro's diversification and growth into new markets, leveraging Oclaro's strong brand, chip design and manufacturing expertise. Oclaro is a global company, with leading chip fabrication facilities in the U.K., Switzerland and Italy, and manufacturing sites in the US, Thailand and China.

Oclaro, the Oclaro logo and all other Oclaro product names and slogans are trademarks or registered trademarks of Oclaro, Inc. in the USA or other countries.


'/>"/>
SOURCE Oclaro, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
3. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Netsmart Technologies Customer in Pennsylvania Recognized for Achieving Data Benchmarking Milestones
6. SPO Medical Announces Major Sales Milestone
7. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
8. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
9. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
10. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
11. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
Breaking Biology News(10 mins):